Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Surgery Partners (SGRY) EBITDA (2016 - 2025)

Historic EBITDA for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $105.7 million.

  • Surgery Partners' EBITDA rose 7356.32% to $105.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $406.4 million, marking a year-over-year increase of 2578.15%. This contributed to the annual value of $493.6 million for FY2024, which is 1197.82% up from last year.
  • According to the latest figures from Q3 2025, Surgery Partners' EBITDA is $105.7 million, which was up 7356.32% from $111.7 million recorded in Q2 2025.
  • Over the past 5 years, Surgery Partners' EBITDA peaked at $127.1 million during Q4 2024, and registered a low of $46.4 million during Q1 2023.
  • Over the past 5 years, Surgery Partners' median EBITDA value was $82.6 million (recorded in 2023), while the average stood at $84.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 24378.38% in 2021, then tumbled by 5378.49% in 2023.
  • Quarter analysis of 5 years shows Surgery Partners' EBITDA stood at $114.8 million in 2021, then fell by 17.94% to $94.2 million in 2022, then grew by 7.64% to $101.4 million in 2023, then rose by 25.35% to $127.1 million in 2024, then dropped by 16.84% to $105.7 million in 2025.
  • Its EBITDA was $105.7 million in Q3 2025, compared to $111.7 million in Q2 2025 and $61.9 million in Q1 2025.